沈阳治疗白块哪家医院较好(沈阳看灰指甲哪个医院好) (今日更新中)

The Daytona International Speedway announced the Daytona 500 will have limited fan capacity next year due to COVID-19.Organizers said they will continue to work with local and state health officials regarding fan attendance at the 63rd annual event set for Feb. 14."While the stands may not be 101,500 strong, one truth remains: we are as committed as ever to delivering a best-in-class experience at the World Center of Racing for The Great American Race. From the awe of the U.S. Air Force Thunderbirds flyover, to the rumble of 40 engines roaring around the high banks on the biggest stage in motorsports – the DAYTONA 500 is sure to once again deliver the pageantry, thrills, and drama for all fans, especially those able to attend in person." The 63rd Annual #DAYTONA500 will have limited fan capacity. The grandstands may not look the same, but you can rest assured The Great American Race will once again have the aura and atmosphere of the biggest event in motorsports. ??: https://t.co/9cEIKinY8Y pic.twitter.com/ZSTM13Jra3— Daytona International Speedway (@DISupdates) December 2, 2020 Organizers said on its website they will work to accomodate those who have already purchased tickets to the race. "To ensure social distancing between groups who will be in attendance, many fans will be reseated in new locations," organizers said.The speedway is expected to complete the reseating process by early January.Everyone at the racetrack will be screened before they enter the facility and they'll also be required to wear face coverings while maintaining six feet social distancing, organizers said.This story was first reported by Lisette Lopez at WFTS in Tampa Bay, Florida. 1699

The federal government says the fund providing a 0 weekly unemployment insurance boost is running out, but all eligible unemployed workers will still get their share. The Federal Emergency Management Agency says the jobless boost will end up providing benefits for just six weeks. The program was created last month by President Donald Trump to replace a more generous 0-a-week supplement that had been authorized by Congress but expired. So far, billion of the billion set aside for the program has been sent to states and U.S. territories. 563

The fine print of newly released federal guidelines for reopening schools raises serious questions about whether in-person classes should resume at a time when COVID-19 rages around much of the country.Last week, the Centers for Disease Control and Prevention (CDC), under pressure from the White House, released a position paper highlighting “the importance of reopening America’s schools this fall.”But separate guidelines issued for K-12 school administrators, which drew less public attention, are much more cautious.“It is important to consider community transmission risk as schools reopen,” those CDC guidelines state.“Computer simulations from Europe have suggested the school reopenings may further increase transmission risk in communities where transmission is already high.”Buried at the bottom of the new CDC recommendation to re-open schools is a HUGE caveat! #COVID19 poses a low risk to kids “at least in areas with low community transmission.” That’s not where much of the country stands right now. 4/ pic.twitter.com/0D5CPxhlIb— Phil Williams (@NC5PhilWilliams) July 25, 2020 The new CDC guidelines suggest, “If community transmission levels cannot be decreased, school closure is an important consideration.”“Plans for virtual learning should be in place in the event of a school closure.”In Tennessee, several public and private schools are preparing to reopen even as almost every county in the state is showing what the Department of Health considers to be unacceptable rates of transmission of the coronavirus.Last week, the American Academy of Pediatrics issued a dramatic clarification of its statement back in June that "all policy considerations for the coming school year should start with a goal of having students physically present in school.""This does not mean that we recommend that all schools open five days a week from the start of the school year," the academy’s Dr. Sean O'Leary told a congressional committee.“Many parts of the country are currently experiencing uncontrolled spread of COVID-19. While the AAP urges those areas to make in-person learning as the goal, we recognize that many jurisdictions will need to utilize distance learning strategies until cases decline."The vice chair of the academy's committee on infectious diseases, O'Leary told the subcommittee that, where there is uncontrolled community transmission, "it's inevitable that the virus is going to get into the schools, and schools are going to have to shut down."U.S. Surgeon General Jerome M. Adams also told CBS This Morning last week that a community's COVID-19 transmission rate is the single most important determinant of whether schools can safely reopen.School reopening advocates point to the emotional, psychological and educational importance of children being in the classroom – a position that the CDC guidelines reaffirm.“Schools provide safe and supportive environments, structure and routines for children, as well as other needed support services to children and families,” the CDC notes.Children are less likely to become ill when infected with the virus, and younger children are less likely to transmit the virus to others, the report adds.But a large-scale study out of South Korea recently reported that children ages 10-19 -- middle- and high-school ages -- can spread the virus as easily as adults.Also, in searching citations in the new CDC recommendation to re-open schools, it appears to completely leave out the large-scale South Korea study that found teens are likely to spread #COVID19 as readily as adults 5/ https://t.co/ABLPvpKQU5— Phil Williams (@NC5PhilWilliams) July 25, 2020 In addition, a new study – shared by the Tennessee Department of Health last week on Twitter – concluded that “young, previously healthy adults can take a long time to recover from COVID-19.” 3828

The first large head-to-head comparison of two opioid addiction medications found that, although they were equally effective in getting people off of high levels of opioids, users had a significantly more difficult time starting a regimen of naltrexone, compared with buprenorphine.Buprenorphine is commonly known by the the brand name Suboxone, and naltrexone is sold under the brand name Vivitrol.The study, published Tuesday in the Lancet, looked at 570 patients with opioid addiction at eight inpatient treatment centers across the country for 24 weeks. Half of the group was assigned to naltrexone and the other half to bupenorphine.Six percent of those enlisted to use buprenorphine were unable to start their treatment, whereas 28% of those assigned to naltrexone dropped out before starting the therapy. 824

The Food and Drug Administration on Wednesday authorized the first rapid coronavirus test that doesn’t need any special computer equipment to get results.The 15-minute test from Abbott Laboratories will sell for , giving it a competitive edge over similar tests that need to be popped into a small machine. The size of a credit card, the self-contained test is based on the same technology used to test for the flu, strep throat and other infections.It’s the latest cheaper, simpler test to hit the U.S. market, providing new options to expand testing as schools and businesses struggle to reopen and flu season approaches. The FDA also recently greenlighted a saliva test from Yale University that bypasses some of the supplies that have led to testing bottlenecks.Both tests have limitations and neither can be done at home. Several companies are developing rapid, at-home tests, but none have yet won approval. Abbott’s new test still requires a nasal swab by a health worker, like most older coronavirus tests. The Yale saliva test eliminates the need for a swab, but can only be run at high-grade laboratories.And in general, rapid tests like Abbott’s are less accurate than lab-developed tests. The FDA said in a statement announcing the decision that negative results with Abbott’s test may need to be confirmed with a lab test in some cases. The agency granted Abbott’s test an emergency use authorization late Wednesday for patients with suspected COVID-19.The two additions should help expand the number of available tests. The U.S. is now testing about 690,000 people per day, down from a peak of 850,000 daily tests late last month. Many public health experts believe the country will soon need to test vastly more people to find those who are infected, isolate them and contain the virus.The FDA noted that Abbott’s test could be used in a doctor’s office, emergency room or some schools. “Given the simple nature of this test, it is likely that these tests could be made broadly available,” the FDA said.Since the start of the pandemic, nasal swab tests that are sent to a lab have been the standard for COVID-19 screening. While considered highly accurate, the tests rely on expensive, specialized machines and chemicals. Shortages of those supplies have led to repeated delays in reporting results, especially during a spike in cases last month.Government and health experts view rapid tests that can be run outside the laboratory system as key to boosting capacity.“Those screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders,” said Dr. Jonathan Quick of the Rockefeller Foundation, in an interview earlier this month. The nonprofit group has called for the U.S. to conduct about 4 millions per day by October, mostly rapid, point-of-care tests.Abbott’s BinaxNOW is the fourth rapid test that detects COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself. It’s considered a faster, though sometimes less precise, screening method. The other tests need to be inserted into a small machine.Inside the Abbott test is a specially coated strip that interacts with COVID-19 antigens. The patient’s nasal swab is inserted into the card and a few drops of a chemical solution are added. Markings appear on the card to indicate whether the sample is positive or negative — much like a pregnancy test.Two other makers of antigen tests — Quidel and Becton Dickinson have said they haven’t been able to meet demand for the tests. A third, LumiraDx, plans to begin shipping its recently approved antigen tests by the end of this month. Abbott expects to begin shipping tests in September, reaching 50 million tests a month in October.The influx of antigen tests will go a long way toward meeting the Trump administration’s projection that 90 million COVID-19 tests a month will be available by September if needed. But U.S. “testing czar” Adm. Brett Giroir has stressed that the U.S. can contain the outbreak with far fewer tests.“That’s the capacity ... we do not need that many tests to safely and sensibly reopen,” Giroir told reporters on a recent call. He pointed to several key indicators that have been falling, including new infections and hospitalizations, even as testing has slowed.Earlier this month, the FDA authorized Yale’s saliva-based test, which is expected to cut the time and cost compared with similar tests. It’s the fifth COVID-19 saliva tests OK’d by regulators. All require lab processing.Developed by Yale’s School of Public Health, SalivaDirect can use any sterile container to collect a sample, not the special tube needed with earlier tests, and requires less chemicals. Outside experts welcomed the new approach but noted its limitations.“It’s not a rapid test, it’s a laboratory-based test that will still be prone to the same massive delays as any other test,” said Dr. Michael Mina of Harvard University.___Follow Matthew Perrone on Twitter: @ AP_FDAwriter.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5201

来源：资阳报